Welcome to our dedicated page for Ginkgo Bioworks Holdings news (Ticker: DNA), a resource for investors and traders seeking the latest updates and insights on Ginkgo Bioworks Holdings stock.
Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) is a biological product manufacturing company that describes its mission as building the tools that make biology easier to engineer. The DNA stock news page on Stock Titan aggregates company announcements, collaborations, and regulatory updates so investors and observers can follow how Ginkgo’s platform is being applied across sectors.
According to Ginkgo’s public statements, its business spans cell engineering services, biosecurity offerings, modular lab automation, large-scale biological data generation, and agricultural biologicals R&D. News about Ginkgo Bioworks often covers new partnerships with academic institutions, biotechnology companies, and government agencies, as well as updates on projects funded by U.S. health and research organizations. These stories illustrate how the company’s R&D Solutions, Automation, Datapoints, Agriculture, and Biosecurity units are used in real-world programs.
Typical Ginkgo Bioworks news items include announcements of research collaborations in areas like cancer screening, drug safety modeling, and in vivo cell and gene therapy; contracts for high-throughput phenotyping platforms and biosecurity-related capabilities; and agreements to optimize fermentation and bioprocesses for agricultural soil amendments and biological crop solutions. Investors can also find information about extended strategic partnerships in agriculture and other markets.
This page may also surface press releases tied to quarterly financial results, conference presentations, and other investor communications referenced in the company’s filings. By reviewing the DNA news feed, users can see how Ginkgo Bioworks positions its platform, how its collaborations evolve over time, and how its activities relate to the broader biological product manufacturing and synthetic biology landscape.
Ginkgo Bioworks (NYSE: DNA) reported Q2 2025 financial results, with total revenue of $50 million, down from $56 million year-over-year. The company's Cell Engineering revenue grew 8% to $39 million, while Biosecurity revenue declined to $10 million. The company reported a GAAP net loss of $60 million, significantly improved from a $217 million loss in the prior year.
Notably, Ginkgo achieved its $250 million annualized cost reduction target three months ahead of schedule through workforce reductions and site consolidation. The company maintains its 2025 outlook of $167-$187 million in total revenue and aims to reach Adjusted EBITDA breakeven by the end of 2026. Ginkgo also expanded its services, launching new automated ADME profiling and cell-free protein synthesis systems.
Ginkgo Bioworks (NYSE: DNA), a leader in cell programming and biosecurity, has scheduled its Q2 2025 earnings presentation for Thursday, August 7, 2025, at 5:30 p.m. ET. The company will review its business performance for the quarter ended June 30, 2025.
Investors can access the presentation and Q&A session through Ginkgo's investor relations website. Questions can be submitted in advance via X (using #GinkgoResults) or email to investors@ginkgobioworks.com.
Ginkgo Bioworks (NYSE: DNA) has secured a $4.66M contract to deploy its Reconfigurable Automation Carts (RACs) technology at the Environmental Molecular Sciences Laboratory (EMSL) at Pacific Northwest National Laboratory. The project involves constructing a fully integrated workcell with 18 different devices within a modular anaerobic chamber.
The automation platform will enable remote operation of complex anaerobic phenotyping workflows, streamlining research processes for EMSL scientists. The system features a web-based software stack with API gateway access, supporting AI-driven autonomous science capabilities. The platform is expected to be fully operational later this year, advancing research in microbial engineering and biodesign.
Ginkgo Bioworks (NYSE: DNA) has launched a new high-throughput ADME profiling service through Ginkgo Datapoints, leveraging its proprietary RAC automation technology. The service aims to accelerate small molecule drug discovery by providing cost-competitive ADME testing within the United States, matching or beating prices from international vendors, including Chinese competitors.
The service features automated workflows, rapid turnaround times, and AI-compatible datasets designed to help researchers prioritize drug candidates more efficiently. This initiative demonstrates Ginkgo's commitment to delivering affordable, high-quality services to the biopharma industry while keeping operations U.S.-based.
Ginkgo Bioworks (NYSE: DNA) announced a leadership transition as current CFO Mark Dmytruk plans to resign on May 30, 2025. Steven Coen, the company's Chief Accounting Officer, will be promoted to CFO. Coen, who joined Ginkgo in May 2023, brings over 30 years of experience in public accounting and corporate finance leadership. His previous role was Corporate VP and Controller at Charles River Laboratories, overseeing finances for a $4.0 billion revenue organization with 20,000 employees across 150 locations. The transition comes as Ginkgo works toward its goal of reaching Adjusted EBITDA breakeven by the end of 2026.
Twist Bioscience (NASDAQ: TWST) and Ginkgo Bioworks (NYSE: DNA) have revised their 2022 collaboration agreement with new terms. The updated three-year $15 million agreement maintains Ginkgo as a valued customer of Twist's DNA products with preferential pricing and no minimum purchase requirements. As part of the deal, Twist receives licenses and assignments for long DNA technology and related reagents, while Ginkgo retains rights to practice the transferred IP. The agreement involves annual prepayments from Ginkgo for Twist's DNA products.
Phytolon and Ginkgo Bioworks (NYSE: DNA) have achieved a significant milestone in their natural food colors collaboration, nearly tripling manufacturing efficiency. The partnership, initiated in 2022, focuses on developing yeast strains to produce two natural colors: "Beetroot Red" and "Prickly Pear Yellow."
This breakthrough comes amid increasing pressure to eliminate artificial food dyes in the U.S., with FDA Commissioner Marty Makary announcing plans to remove synthetic colors from the food supply by 2026. The FDA has already banned FD&C Red No. 3 due to cancer risks.
The improved production process offers significant advantages:
- Higher production efficiency (3x increase)
- Reduced production costs
- Lower carbon footprint
- Successful coloring in multiple food categories including baked goods, snacks, dairy, and confectioneries
As part of the milestone achievement, Ginkgo will receive additional equity in Phytolon, strengthening their partnership in sustainable food coloring solutions.
Ginkgo Bioworks (NYSE: DNA), a leader in cell programming and biosecurity, has scheduled its Q1 2025 earnings presentation for Tuesday, May 6, 2025, at 5:30 p.m. ET. The company will review its business performance for the quarter ended March 31, 2025.
The presentation will be accessible through Ginkgo's investor relations website at investors.ginkgobioworks.com, with a replay option available. Stakeholders can submit questions beforehand via:
- X (formerly Twitter) using @Ginkgo and #GinkgoResults
- Email at investors@ginkgobioworks.com
Ginkgo Bioworks (NYSE: DNA) has announced a strategic partnership with Aura Genetics to deploy its Reconfigurable Automation Cart (RAC) system at Aura's new high-throughput facility in Louisville, KY. The collaboration aims to enhance Aura's direct-to-consumer testing capabilities.
The RAC system will be installed at Aura's new 22,000-square-foot facility at the UPS Healthcare Labport. With Ginkgo's automation technology and support services, Aura Genetics expects to process tens of thousands of samples daily. The agreement includes comprehensive support through joint protocol development, biovalidation, and dedicated technical assistance.